VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
326
DELISTED
Allakos
ALLK
| $168K | 0.09% |
+19,981
| New | +$168K |
|
327
Immunovant
IMVT
$2.99B
| $165K | 0.09% |
9,276
-21,091
| -69% | -$374K |
|
|
CERE
328
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $164K | 0.09% |
5,211
+916
| +21% | +$28.9K |
|
329
Runway Growth Finance
RWAY
$387M
| $164K | 0.09% |
14,165
+2,346
| +20% | +$27.2K |
|
330
Design Therapeutics
DSGN
$368M
| $162K | 0.08% |
15,774
+7,999
| +103% | +$82.1K |
|
331
BioXcel Therapeutics
BTAI
$55M
| $158K | 0.08% |
458
-252
| -35% | -$86.7K |
|
332
Crinetics Pharmaceuticals
CRNX
$3.35B
| $157K | 0.08% |
8,598
+2,370
| +38% | +$43.4K |
|
333
Merus
MRUS
$5.11B
| $156K | 0.08% |
10,106
+4,886
| +94% | +$75.6K |
|
|
SWTX
334
DELISTED
SpringWorks Therapeutics
SWTX
| $155K | 0.08% |
5,978
+827
| +16% | +$21.5K |
|
335
Protagonist Therapeutics
PTGX
$3.77B
| $155K | 0.08% |
14,235
-2
| -0% | -$22 |
|
336
Celldex Therapeutics
CLDX
$1.52B
| $155K | 0.08% |
3,480
-1,367
| -28% | -$60.9K |
|
337
Cytokinetics
CYTK
$6.35B
| $155K | 0.08% |
3,383
+718
| +27% | +$32.9K |
|
338
Edgewise Therapeutics
EWTX
$1.64B
| $155K | 0.08% |
17,314
-155
| -0.9% | -$1.39K |
|
339
Stoke Therapeutics
STOK
$1.14B
| $154K | 0.08% |
16,715
+6,745
| +68% | +$62.3K |
|
340
Atea Pharmaceuticals
AVIR
$267M
| $153K | 0.08% |
31,762
+16,102
| +103% | +$77.5K |
|
|
IMAB
341
I-MAB
IMAB
$360M
| $152K | 0.08% |
36,476
+24,945
| +216% | +$104K |
|
|
RETA
342
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $151K | 0.08% |
3,975
+371
| +10% | +$14.1K |
|
343
RAPT Therapeutics
RAPT
$218M
| $151K | 0.08% |
953
+76
| +9% | +$12K |
|
|
PNT
344
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $150K | 0.08% |
20,629
+5,494
| +36% | +$40.1K |
|
345
IDEAYA Biosciences
IDYA
$2.38B
| $150K | 0.08% |
8,259
-897
| -10% | -$16.3K |
|
346
Nuvation Bio
NUVB
$1.33B
| $149K | 0.08% |
77,816
+47,366
| +156% | +$90.9K |
|
347
FibroGen
FGEN
$48.5M
| $149K | 0.08% |
372
-94
| -20% | -$37.6K |
|
348
AnaptysBio
ANAB
$612M
| $148K | 0.08% |
4,774
-253
| -5% | -$7.84K |
|
|
AFMD
349
DELISTED
Affimed
AFMD
| $147K | 0.08% |
11,870
+7,269
| +158% | +$90.1K |
|
|
KDNY
350
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $147K | 0.08% |
5,610
-880
| -14% | -$23.1K |
|